Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 28, 2024 (filed on Mar 29, 2024)Insider Name:Roberts Brian KennethOwnership Type:Indirect OwnershipSecurities:Common SharesNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:500Price:$2.55
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Evans DaronOwnership Type:Indirect OwnershipSecurities:Common SharesNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:20,000Price:$1.69
-
Mar 14, 2024 (filed on Mar 18, 2024)Insider Name:Roberts Brian KennethOwnership Type:Indirect OwnershipSecurities:Common SharesNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:10,000Price:$1.88
-
Mar 08, 2024 (filed on Mar 08, 2024)Insider Name:Evans DaronOwnership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:50,000Price:$1.93
-
Mar 07, 2024 (filed on Mar 18, 2024)Insider Name:Roberts Brian KennethOwnership Type:Indirect OwnershipSecurities:Common SharesNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:500Price:$1.85
-
Mar 07, 2024 (filed on Mar 14, 2024)Insider Name:Kim Young-JinOwnership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:36,503Price:$1.91
-
Mar 07, 2024 (filed on Mar 11, 2024)Insider Name:Roberts Brian KennethOwnership Type:Indirect OwnershipSecurities:Common SharesNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:500Price:$1.85
-
Feb 26, 2024 (filed on Feb 28, 2024)Insider Name:Elam Nevan COwnership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:5,000Price:$1.68
-
Feb 26, 2024 (filed on Feb 27, 2024)Insider Name:Roberts Brian KennethOwnership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:2,000Price:$1.70
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Roberts Brian KennethOwnership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:6,000Price:$1.69
Filings by filing date
-
Mar 28, 2024 (filed on Mar 29, 2024)Insider Name:Roberts Brian KennethOwnership Type:Indirect OwnershipSecurities:Common SharesNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:500Price:$2.55
-
Jul 22, 2022 (filed on Mar 19, 2024)Insider Name:Handok, Inc.Ownership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:3,157,895Price:$3.80
-
Oct 15, 2021 (filed on Mar 19, 2024)Insider Name:Handok, Inc.Ownership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:769,231Price:$6.50
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Evans DaronOwnership Type:Indirect OwnershipSecurities:Common SharesNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:20,000Price:$1.69
-
Mar 14, 2024 (filed on Mar 18, 2024)Insider Name:Roberts Brian KennethOwnership Type:Indirect OwnershipSecurities:Common SharesNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:10,000Price:$1.88
-
Mar 07, 2024 (filed on Mar 18, 2024)Insider Name:Roberts Brian KennethOwnership Type:Indirect OwnershipSecurities:Common SharesNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:500Price:$1.85
-
Mar 07, 2024 (filed on Mar 14, 2024)Insider Name:Kim Young-JinOwnership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:36,503Price:$1.91
-
Jul 22, 2022 (filed on Mar 14, 2024)Insider Name:Kim Young-JinOwnership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:78,947Price:$3.80
-
Mar 07, 2024 (filed on Mar 11, 2024)Insider Name:Roberts Brian KennethOwnership Type:Indirect OwnershipSecurities:Common SharesNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:500Price:$1.85
-
Mar 08, 2024 (filed on Mar 08, 2024)Insider Name:Evans DaronOwnership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:50,000Price:$1.93
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 275 Shoreline Drive, Suite 500 REDWOOD CITY CA 94065 |
Tel: | N/A |
Website: | https://www.rezolutebio.com |
IR: | See website |
Key People | ||
Nevan Charles Elam Acting Chairman of the Board, Chief Executive Officer | Daron Evans Chief Financial Officer | Brian K. Roberts Chief Medical Officer |
Business Overview |
Rezolute, Inc. is a clinical-stage biopharmaceutical company, which is developing therapies for metabolic diseases related to chronic glucose imbalance. The Company's lead clinical asset, RZ358, is in late-stage development for the treatment of congenital hyperinsulinism (HI), an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas in Phase III. RZ358 is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat and muscle. Its second clinical asset, RZ402, is an oral plasma kallikrein inhibitor (PKI) being developed as a therapy for the chronic treatment of diabetic macular edema (DME) in Phase II. RZ402 is designed to be a once daily oral therapy for the treatment of DME and unlike the anti-VEGF therapies, RZ402 targets the Kallikrein-Kinin System to address inflammation and vascular leakage. |
Financial Overview |
For the six months ended 31 December 2023, Rezolute Inc revenues was not reported. Net loss increased 22% to $28.4M. Higher net loss reflects Research and development - Balancing val increase of 32% to $22.3M (expense), General and administrative - Balancing increase of 23% to $4.8M (expense), Stock-based Compensation in R&D increase of 5% to $1.7M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.46 to -$0.55. |
Employees: | 51 as of Jun 30, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $14.14M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$62.45M as of Dec 31, 2023 |
Net annual income (TTM): | -$56.83M as of Dec 31, 2023 |
Free cash flow (TTM): | -$53.00M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 40,127,647 as of Mar 18, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |